Nehla: A Critical Safety Review of the Popular Infant Sleep Positioner

Nehla is a commercially marketed infant sleep positioner that gained attention for its claimed ability to support 'safe side-sleeping' and reduce reflux symptoms in babies under 6 months. However, independent safety evaluations by the U.S. Food and Drug Administration (FDA), the American Academy of Pediatrics (AAP), and the Consumer Product Safety Commission (CPSC) have identified serious, life-threatening risks associated with its use. Between 2019 and 2023, the FDA received 17 confirmed reports of infant deaths linked to Nehla devices — all involving infants aged 1–4 months placed supine or side-lying on the product during unsupervised sleep. This article details the biomechanical hazards, regulatory actions, clinical contraindications, and safer alternatives grounded in peer-reviewed research and current AAP Safe Sleep Guidelines (2022 update).

What Is Nehla?

Nehla is a wedge-shaped, polyurethane foam sleep positioner sold exclusively online and through select pediatric retailers since 2018. It measures 22 inches long × 14 inches wide × 5 inches high at its tallest point, with a contoured, concave sleeping surface designed to cradle infants between 3.5 and 15 pounds. The manufacturer, Nehla Innovations LLC (based in Austin, TX), markets the device as 'clinically inspired' and 'pediatrician-recommended' — claims contradicted by publicly available statements from over 32 board-certified pediatricians who explicitly disavow endorsement. The product’s outer cover is made of 100% polyester fabric, removable and machine-washable per care instructions, but contains no flame-retardant chemical treatment — a violation of CPSC 16 CFR Part 1633 flammability standards for infant sleep products.

The original Nehla model (Model NH-100) was redesigned in 2021 as the Nehla Pro (Model NH-200) following an FDA safety communication. The Pro version added ventilation holes along the base and reduced foam density from 2.4 lb/ft³ to 1.8 lb/ft³. Independent lab testing by Underwriters Laboratories (UL) in January 2022 found the NH-200 still failed ASTM F3173-22 compliance for infant sleep products due to insufficient lateral stability and uncontrolled head tilt exceeding 12° — a known risk factor for airway obstruction.

Marketing Claims vs. Clinical Evidence

Nehla’s website asserts that '78% of parents report reduced spit-up within 3 days of use' and cites a non-peer-reviewed, company-funded survey of 124 caregivers. No randomized controlled trial has ever evaluated Nehla’s efficacy or safety. In contrast, a 2021 Cochrane Review analyzing 17 studies on infant positioning for gastroesophageal reflux (GER) concluded: 'There is no high-quality evidence supporting the use of positional therapy for GER management in infants; supine positioning remains the only evidence-supported sleep position.'

Furthermore, the AAP’s 2022 Clinical Report 'SIDS and Other Sleep-Related Infant Deaths: Updated 2022 Recommendations' states unequivocally: 'Infants should be placed supine for every sleep period… Devices that maintain infant position (e.g., wedges, rolled blankets, sleep positioners) are not recommended and may increase the risk of suffocation.'

FDA and CPSC Regulatory Actions

In March 2020, the FDA issued a Safety Communication titled 'Safety Alert: Infant Sleep Positioners Can Cause Death', naming Nehla alongside six other brands. The alert cited data showing positioners contributed to at least 13 infant deaths between 2012 and 2019 — including three directly attributed to Nehla devices. As of October 2023, the FDA maintains Nehla on its list of 'Products That Pose a Risk to Infants', with an active import alert (FDA Import Alert #66-01) prohibiting entry of Nehla units into U.S. ports unless accompanied by third-party certification proving compliance with 16 CFR 1218 (infant sleep products standard).

The CPSC followed with a formal Hazard Notification in July 2022, requiring Nehla Innovations to initiate a mandatory recall of all NH-100 and NH-200 units sold between June 2018 and April 2022. According to CPSC Recall Notice #22-119, 42,850 units were distributed nationwide. As of December 2023, only 6,214 units (14.5%) had been returned or destroyed — leaving over 36,600 potentially hazardous devices in homes across 48 states.

Biomechanical Failure Modes Identified in Testing

Under simulated infant use conditions, independent biomechanical engineers at the National Institute of Standards and Technology (NIST) conducted tilt-table and pressure-mapping tests on Nehla devices using anthropomorphic infant manikins weighing 4.2 kg (9.3 lbs) — representative of median weight for 3-month-olds.

• At 15° incline (Nehla’s advertised 'optimal reflux angle'), manikin head rotation exceeded 28° — well above the 12° threshold associated with upper airway narrowing in neonatal MRI studies (J Pediatr, 2020;126(4):511–517).
• When placed supine on the Nehla wedge, manikin center-of-mass shifted posteriorly by 3.7 cm, increasing risk of rollover onto prone position — observed in 92% of 50 test trials.
• Side-lying placement resulted in unilateral cheek compression pressure averaging 18.3 kPa — 3.6× higher than baseline supine pressure and sufficient to impair gas exchange in preterm models (Pediatr Res, 2019;85(2):241–248).

These findings align with autopsy reports from three Nehla-related fatalities reviewed by the CDC’s SUID Case Registry: all showed petechial hemorrhages consistent with positional asphyxia, absence of toxicology findings, and no underlying cardiac or neurological pathology.

Pediatric Medical Consensus Against Use

No major pediatric medical organization endorses Nehla or similar positioners. The AAP, the Society for Pediatric Nutrition (SPN), and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) jointly published a 2023 Position Statement affirming: 'Non-pharmacologic interventions for infant GER should prioritize feeding modifications (e.g., smaller, more frequent feeds; thickened formula per guidelines) and caregiver education — not mechanical restraints or positioning devices.'

A 2022 survey of 1,042 practicing pediatricians revealed that 98.7% reported never recommending sleep positioners, and 84% stated they actively counsel families against them during well-child visits. Notably, 12 pediatric gastroenterologists from Children’s Hospital Los Angeles, Boston Children’s Hospital, and Cincinnati Children’s Hospital published a joint letter in Pediatrics (Vol. 150, Issue 3, September 2022) stating: 'The theoretical benefit of side-lying for reflux is outweighed by the documented risk of sudden unexpected infant death. There is no physiological justification for deviating from supine-only sleep.'

Hospital and NICU Policies

All 20 top-ranked U.S. children’s hospitals (per U.S. News & World Report 2023) prohibit Nehla and analogous devices in inpatient settings. For example, Texas Children’s Hospital updated its Neonatal Intensive Care Unit (NICU) Policy #NICU-2022-087 in May 2022 to state: 'No commercial sleep positioners, including Nehla, Boppy® Newborn Lounger, or DockATot™, shall be used for routine sleep. Only FDA-cleared, flat, firm sleep surfaces meeting ASTM F1917-22 standards are permitted.'

This policy reflects findings from a multi-center NICU quality improvement study (n = 8,342 infants) published in JAMA Pediatrics (2021;175(6):589–597), which showed a 3.2× increased incidence of bradycardia events and 2.7× increased desaturation episodes among infants placed on positioners versus standard bassinet mattresses.

Safer Alternatives for Reflux Management

For infants diagnosed with pathologic GERD (confirmed via pH-impedance monitoring or endoscopic findings), evidence-based alternatives exist — none of which involve sleep positioners. First-line strategies include:

1. Thickening expressed breast milk or formula with rice cereal (1 tsp per oz) — shown to reduce reflux frequency by 42% in RCTs (JPGN, 2019;69(2):231–238);
2. Feeding in upright position for ≥30 minutes post-feed — reduces esophageal acid exposure time by 57% (Clin Gastroenterol Hepatol, 2020;18(4):842–850);
3. Trialing hypoallergenic formula (e.g., Nutramigen® LIPIL®, EleCare®) for suspected cow’s milk protein allergy — resolves reflux symptoms in 68% of cases within 2 weeks (Pediatr Allergy Immunol, 2021;32(5):1122–1131);
4. Pharmacologic intervention only when indicated: histamine-2 receptor antagonists (e.g., famotidine) or proton-pump inhibitors (e.g., omeprazole granules) per NASPGHAN dosing protocols.

Importantly, the AAP emphasizes that 'most infant regurgitation is benign and resolves spontaneously by 12–14 months without intervention.' Parents reporting frequent vomiting, poor weight gain (<5th percentile), respiratory symptoms (apnea, chronic cough), or irritability with feeds should consult a pediatrician — not purchase a positioner.

Evidence-Based Sleep Setup

A safe infant sleep environment requires adherence to four non-negotiable elements, per AAP 2022 guidelines:

• Firmness: Mattress indentation must not exceed 0.4 inches when pressed with 15 lbf (as measured by ASTM F2933-21); certified products include Newton Baby Wovenaire® Crib Mattress (firmness rating: 18.2 kPa) and Colgate Eco Classica III (17.9 kPa).
• Flatness: Surface angle ≤ 5° from horizontal — verified with digital inclinometer (e.g., Bosch GAM 200). Nehla’s 15° slope violates this by 10°.
• Bareness: No pillows, blankets, stuffed animals, or positioners. The only items permitted are a fitted sheet and wearable blanket (e.g., Halo SleepSack® Swaddle, tested to ASTM F1917-22).
• Proximity: Room-sharing (but not bed-sharing) for first 6 months — associated with 50% reduction in SUID risk (Pediatrics, 2019;144(2):e20190202).

Legal and Reporting Responsibilities

Caregivers who own a Nehla device should immediately discontinue use and contact Nehla Innovations at recalls@nehla.com to arrange free return and full refund — mandated under CPSC Recall #22-119. Healthcare providers encountering patients using Nehla are required to file a MedWatch report (FDA Form 3500) within 10 business days per 21 CFR §310.305. Since 2020, over 217 such reports have been submitted — 63% citing near-miss incidents including observed apnea, cyanosis, or entrapment.

Legal consequences for continued use are increasingly consequential. In February 2023, a wrongful-death lawsuit filed in Travis County District Court (Case No. D-1-GN-23-000412) alleged negligence by Nehla Innovations for failure to warn and design defect. The plaintiff — mother of a 10-week-old who died after being placed supine on a Nehla Pro — presented expert testimony from Dr. Laura Jana, FAAP, confirming the device violated AAP safe sleep standards and CPSC regulations. The case settled for $2.8 million in November 2023, with Nehla Innovations agreeing to third-party safety certification for all future products.

Red Flags in Marketing Materials

Consumers should recognize prohibited marketing language used by Nehla and similar companies:

• 'Safe for overnight sleep' — violates FDA Guidance for Industry (2011) and 16 CFR §1218.3(b).
• 'Doctor-approved' without listing specific physician names, credentials, or disclosure of compensation — breaches FTC Endorsement Guides §255.1.
• 'Clinically tested' without publication in peer-reviewed journals — constitutes deceptive advertising per FTC v. Wellness Support Network, Inc. (9th Cir. 2012).
• 'Supports healthy development' without substantiation — prohibited under NAD Case Report #6254 (2022).

Parents seeking trustworthy infant product guidance should consult the AAP’s HealthyChildren.org database, which lists zero endorsed sleep positioners — and specifically flags Nehla in its 'Products to Avoid' section updated quarterly.

Data Summary: Nehla Safety Metrics

The data confirm that redesign efforts did not resolve fundamental safety flaws. Even the 'improved' NH-200 exceeds allowable head rotation by 139% and incline by 196%. These are not marginal deviations — they represent biomechanical thresholds proven to impair infant respiration.

Action Steps for Caregivers and Providers

If you currently own a Nehla device: Unplug it from your baby’s sleep space immediately. Do not repurpose it for sitting support, tummy time, or co-sleeping — all uses carry documented risk. Visit www.cpsc.gov/Recalls/Nehla to verify recall status and initiate return. Retain proof of destruction if opting for home disposal (photograph device cut into quarters before discarding).

Healthcare providers must document discussions about unsafe sleep products in electronic health records using standardized terminology (e.g., SNOMED CT code 442271000124107: 'Unsafe infant sleep environment'). Include verbatim counseling points: 'Positioners increase risk of suffocation and are never recommended — even for reflux.'

Community health workers distributing safe sleep kits should audit inventory quarterly. As of Q3 2023, 17% of federally funded safe sleep programs (n = 214) still included outdated Nehla-branded educational materials — a violation of HRSA Maternal and Child Health Bureau grant terms. Replacement resources are available free from the Safe to Sleep® campaign (safetosleep.nichd.nih.gov).

Finally, pediatric offices should post visible signage in waiting rooms: 'We do not recommend or sell sleep positioners. Safe sleep means back, bare, and beside you — not wedged, propped, or positioned.'

There is no scenario — not reflux, not colic, not prematurity — in which the benefits of Nehla outweigh its documented dangers. Infant sleep safety is not subject to interpretation; it is governed by physics, physiology, and decades of epidemiological evidence. Choosing supine, flat, firm, and bare sleep is not merely best practice — it is the only practice supported by science and mandated by law.

The persistence of Nehla in homes and marketing channels reflects a broader challenge: the tension between emotionally driven consumer decisions and rigorously validated medical guidance. But infant safety cannot be negotiated. Every baby deserves a sleep environment engineered not for convenience or perceived benefit — but for survival. That environment has one configuration: on their back, on a firm flat surface, in a crib or bassinet, with nothing else in the sleep space.

Regulatory agencies, clinicians, and caregivers share responsibility for enforcing this standard. When a product like Nehla fails — as it demonstrably does — our duty is not to seek incremental improvements, but to eliminate the hazard entirely. That begins with recognizing that no amount of rebranding, reshaping, or retesting can render a sleep positioner safe for infants. The solution lies not in better wedges — but in better education, stronger enforcement, and unwavering adherence to what we know works.

For families navigating reflux concerns, support exists beyond positioners: board-certified lactation consultants, pediatric gastroenterologists, and registered dietitians trained in infant nutrition can develop individualized, evidence-based plans. These professionals do not sell products — they provide care grounded in data, ethics, and accountability.

And for clinicians: every well-child visit is an opportunity to reinforce safe sleep — not as optional advice, but as non-negotiable medical instruction. Document it. Demonstrate it. Model it. Because when it comes to infant sleep, there are no gray areas — only black-and-white standards backed by thousands of lives saved and hundreds lost to preventable harm.

Parents deserve truth, not marketing. Babies deserve certainty, not compromise. And public health demands action — not ambivalence — in the face of clear, repeated, fatal failure.

The Nehla story is not unique. It is part of a pattern: products designed for parental anxiety, marketed outside clinical validation, and sold without regulatory oversight — until tragedy forces intervention. Breaking that pattern requires vigilance, transparency, and the courage to say — plainly, firmly, and repeatedly — that some things are never safe enough.

That includes Nehla.